broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K53972329-001-07-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 23.327488 | 0.126348 | -0.000248 | 1 | 101,553,788,517,780,400,000,000,000 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000905 |
BRD-K54256913-001-08-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.060702 | 1.438137 | 0.769908 | 0.681762 | 0.37558 | 0.410952 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000905 |
BRD-K54955827-001-02-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.209172 | 2.235118 | 0.600921 | 0.849076 | 1.580429 | 2.013988 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000905 |
BRD-K54997624-001-06-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.553991 | 3.597024 | 0.430338 | 0.788456 | 0.100223 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000905 |
BRD-K55187425-236-05-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.377902 | 4.806786 | 0.589237 | 0.555332 | 0.009714 | 0.013025 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000905 |
BRD-K56343971-001-14-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.198007 | 0.585066 | 0.313408 | 0.746218 | 0.610163 | 1.444483 | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000905 |
BRD-K56981171-001-02-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.069128 | 2.217854 | 0.522843 | 0.872774 | 2.720064 | 2.908816 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000905 |
BRD-K57169635-001-04-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.003984 | 0.575901 | 0.85714 | 0.648836 | 0.404333 | 0.409991 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000905 |
BRD-K58435339-001-03-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.155838 | 6.844261 | 0.830078 | 0.61007 | 0.113029 | 0.119368 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000905 |
BRD-K58529924-001-01-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.615022 | 8.74247 | 0.261432 | 0.920652 | 1.43379 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000905 |
BRD-K58550667-001-08-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.114594 | 4.038963 | 0.641526 | 0.752056 | 0.041262 | 0.044009 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000905 |
BRD-K59317601-001-05-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.324431 | 0.553576 | 0.614153 | 0.667636 | 0.085394 | 0.565578 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000905 |
BRD-K59369769-001-22-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.109969 | 0.548689 | 0.59479 | 0.622701 | 0.18327 | 0.288197 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000905 |
BRD-K60866521-001-07-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.032789 | -3.063535 | 0.142816 | 0.980898 | 0.000567 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000905 |
BRD-K60997853-001-02-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.149183 | 1.190453 | 0.552009 | 0.636878 | 0.159723 | 0.215097 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000905 |
BRD-K61192372-001-08-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.640073 | -0.079306 | -0.029459 | 0.750208 | 2,688.592043 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000905 |
BRD-K62008436-001-23-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.078432 | 0.530126 | 0.622351 | 0.333639 | 0.000349 | 0.000482 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000905 |
BRD-K62196610-001-01-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.305405 | 0.197925 | 0.106081 | 0.599964 | 0.014812 | 1.743014 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000905 |
BRD-K62200014-003-10-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 16.598742 | 0.609299 | -0.122872 | 1 | 210,687,269,467.7824 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000905 |
BRD-K62391742-001-09-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.748291 | -0.481006 | 0.112797 | 0.846423 | 0.290115 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000905 |
BRD-K63504947-001-14-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 1.377404 | 0.260172 | 0.084742 | 1 | 0.257454 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000905 |
BRD-K63712959-001-01-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.658775 | -0.515017 | 0.116587 | 0.907113 | 0.005072 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000905 |
BRD-K64052750-001-22-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.332387 | 0.767126 | 0.745202 | 0.775229 | 0.421796 | 1.753306 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000905 |
BRD-K64881305-001-03-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.068728 | 1.588442 | 0.795984 | 0.373173 | 0.014501 | 0.015916 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000905 |
BRD-K66175015-001-12-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.322437 | 2.398389 | 0.773516 | 0.672122 | 0.091303 | 0.140589 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000905 |
BRD-K67844266-003-01-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.35865 | 3.797985 | 0.483133 | 0.616989 | 0.03041 | 0.042411 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000905 |
BRD-K69001009-001-02-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.718817 | 5.254201 | 0.144359 | 0.903361 | 0.35602 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000905 |
BRD-K69694239-001-02-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.176533 | 1.459907 | 0.458084 | 0.653407 | 0.16856 | 0.227149 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000905 |
BRD-K69776681-001-03-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.28522 | 5.00402 | 0.620143 | 0.511362 | 0.013145 | 0.015563 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000905 |
BRD-K70301465-001-05-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.443519 | 0.769201 | 0.637778 | 0.745932 | 0.121588 | 2.070778 | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000905 |
BRD-K70401845-001-15-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.316814 | 2.168382 | 0.830179 | 0.857631 | 1.33112 | 2.115108 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000905 |
BRD-K73838513-003-05-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.141507 | 5.782276 | 0.312057 | 0.907808 | 3.528375 | 3.737344 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000905 |
BRD-K74514084-003-09-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.504282 | 4.920156 | 0.388973 | 0.813906 | 0.261697 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000905 |
BRD-K75009076-001-02-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.213578 | 4.572657 | 0.561923 | 0.777059 | 0.638551 | 0.721292 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000905 |
BRD-K76239644-001-02-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.266178 | 0.614851 | 0.557462 | 0.716058 | 0.265876 | 0.915232 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000905 |
BRD-K76674262-001-03-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.158283 | 2.589 | 0.698382 | 0.571482 | 0.071501 | 0.082826 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000905 |
BRD-K76908866-001-07-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.775627 | 1.214404 | 0.072607 | 0.844746 | 0.011862 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000905 |
BRD-K77625799-001-07-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.723496 | 0.394355 | 0.107045 | 0.888318 | 0.277319 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000905 |
BRD-K78431006-001-15-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.669675 | 7.511509 | 0.334535 | 0.835473 | 0.079574 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000905 |
BRD-K79254416-001-21-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.609791 | 0.240621 | 0.002615 | 0.729643 | 0.001863 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000905 |
BRD-K81016934-001-02-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.702605 | -0.389421 | 0.06056 | 0.885147 | 0.017122 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000905 |
BRD-K81418486-001-44-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.181131 | 0.467542 | 0.593151 | 0.648652 | 0.968188 | 0.499799 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000905 |
BRD-K81473043-001-19-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.192488 | 8.301994 | 0.538988 | 0.802725 | 0.058367 | 0.061887 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000905 |
BRD-K82135108-001-04-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.199706 | 1.44072 | 0.407133 | 0.605125 | 0.083268 | 0.118623 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000905 |
BRD-K82746043-001-19-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.150194 | 0.925157 | 0.479408 | 0.344046 | 0.004813 | 0.007081 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000905 |
BRD-K82818427-001-04-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.45848 | 4.512356 | 0.352838 | 0.820147 | 0.398289 | 0.69135 | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000905 |
BRD-K83029223-001-01-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.083437 | 9.681702 | 0.812332 | 0.56278 | 0.006099 | 0.006215 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000905 |
BRD-K83988098-001-02-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.0879 | 0.320171 | 0.360917 | 0.620046 | 0.01224 | 0.007381 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000905 |
BRD-K85402309-043-01-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.26269 | 0.415306 | 0.119851 | 0.649911 | 0.107528 | 0.646907 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000905 |
BRD-K85606544-001-09-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.1518 | 0.489277 | 0.577632 | 0.626165 | 0.156535 | 0.327932 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000905 |
BRD-K86118762-001-01-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.722778 | -0.064846 | -0.022028 | 0.866064 | 0.027352 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000905 |
BRD-K87737963-001-06-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.734884 | -0.475497 | -0.031003 | 0.921681 | 0.00626 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000905 |
BRD-K87782578-001-01-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.147969 | 3.432531 | 0.554559 | 0.911354 | 3.677213 | 4.072997 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000905 |
BRD-K87909389-003-03-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.171006 | 5.986836 | 0.706913 | 0.717494 | 0.366199 | 0.392714 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000905 |
BRD-K88510285-001-17-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.173602 | 0.363401 | 0.633316 | 0.443003 | 0.027716 | 0.012206 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000905 |
BRD-K89014967-001-04-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.455887 | 0.648339 | 0.269078 | 0.572923 | 0.003137 | 0.132673 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000905 |
BRD-K92441787-001-04-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.650251 | -0.045587 | -0.042616 | 0.795376 | 151.012915 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000905 |
BRD-K92723993-001-17-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 23.161142 | 12.838306 | -0.003918 | 1 | 563,731.893708 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000905 |
BRD-K95142244-001-01-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.415272 | 1.891069 | 0.602566 | 0.662622 | 0.036993 | 0.094578 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000905 |
BRD-K96123349-236-02-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.625617 | 4.734723 | 0.363095 | 0.811755 | 0.075998 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000905 |
BRD-K98572433-001-02-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.411378 | 1.065082 | 0.753498 | 0.697713 | 0.068375 | 0.347058 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000905 |
BRD-K99113996-001-02-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.689804 | 3.021157 | 0.241733 | 0.784622 | 0.011847 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000905 |
BRD-K99616396-001-05-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.62568 | -0.364861 | 0.054749 | 0.839668 | 0.02913 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000905 |
BRD-K99749624-001-07-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.714432 | 1.823247 | 0.207993 | 0.929782 | 0.9263 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000905 |
BRD-K02130563-001-11-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.095374 | 1.090215 | 0.754076 | 0.503068 | 0.048148 | 0.058465 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000906 |
BRD-K03390685-001-01-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.175279 | 1.217224 | 0.454375 | 0.773493 | 0.718746 | 1.024663 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000906 |
BRD-K03406345-001-21-1 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.305886 | 0.502445 | 0.27869 | 0.845179 | 2.485453 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000906 |
BRD-K03765900-001-01-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.939989 | 0.076918 | -0.034095 | 0.975548 | 10.74405 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000906 |
BRD-K05804044-001-18-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.63892 | 0.147243 | 0.039567 | 0.852944 | 1.110947 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000906 |
BRD-K06814349-304-02-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.393155 | 5.846672 | 0.501149 | 0.793305 | 0.366827 | 0.477631 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000906 |
BRD-K08109215-001-06-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.794124 | 5.289916 | 0.191588 | 0.926311 | 0.310059 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000906 |
BRD-K08547377-001-04-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.194468 | 0.630262 | 0.448044 | 0.674566 | 0.218716 | 0.477841 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000906 |
BRD-K08703257-001-13-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.238929 | -0.337451 | -0.04991 | 1 | 0.000344 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000906 |
BRD-K08799216-001-05-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.583656 | 0.565575 | -0.035718 | 0.925815 | 4.006434 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000906 |
BRD-K09951645-001-11-8 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.594124 | 1.404192 | 0.35257 | 0.721263 | 0.012625 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000906 |
BRD-K13049116-001-04-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.72958 | -0.631521 | -0.011881 | 0.835229 | 0.252671 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000906 |
BRD-K17555800-003-02-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.056706 | 5.870513 | 0.019108 | 1 | 0.036709 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000906 |
BRD-K17610631-001-03-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.089228 | 0.87095 | 0.686828 | 0.664744 | 0.285138 | 0.357334 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000906 |
BRD-K17894950-001-14-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.197231 | -0.292405 | 0.026248 | 1 | 0.092557 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000906 |
BRD-K18961567-001-01-1 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.268218 | 9.619572 | 0.413895 | 0.95516 | 5.519416 | 5.978642 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000906 |
BRD-K22822991-001-02-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.444408 | -0.917571 | -0.017655 | 0.869642 | 0.005155 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000906 |
BRD-K23984367-001-07-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.378917 | 1.214607 | 0.451908 | 0.912852 | 3.051485 | 9.807974 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000906 |
BRD-K28822270-001-03-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.368187 | 2.444082 | 0.411183 | 0.810075 | 0.566234 | 0.977004 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000906 |
BRD-K29905972-001-06-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.633381 | 0.186891 | -0.059642 | 0.764295 | 0.002732 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000906 |
BRD-K31928526-001-02-1 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 2.396325 | 0.021075 | -0.099624 | 1 | 153,728,530,236,864,060,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000906 |
BRD-K33610132-001-02-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.202479 | 2.723916 | 0.024958 | 1 | 0.024778 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000906 |
BRD-K35520305-001-16-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.075058 | 0.768392 | 0.006981 | 1 | 0.002951 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000906 |
BRD-K36788280-001-01-2 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.626857 | 5.058141 | 0.115589 | 0.995101 | 10.199413 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000906 |
BRD-K38332599-001-01-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.181715 | -0.321373 | 0.02095 | 1 | 0.214193 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000906 |
BRD-K38527262-300-01-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.446983 | 28.747669 | 0.277055 | 0.970796 | 1.483076 | 1.60348 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000906 |
BRD-K42495768-001-01-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.619576 | -0.11613 | -0.016476 | 0.868385 | 0.000282 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000906 |
BRD-K42828737-001-03-3 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.82086 | 1.204987 | 0.107267 | 0.901945 | 0.02619 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000906 |
BRD-K43389675-001-02-1 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.039831 | 0.897344 | 0.782086 | 0.581341 | 0.147809 | 0.162138 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000906 |
BRD-K44408410-001-17-6 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.568837 | 4.401973 | 0.213914 | 0.891831 | 0.876262 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000906 |
BRD-K46386702-001-02-1 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.687429 | -0.453674 | -0.036957 | 0.884196 | 0.015856 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000906 |
BRD-K49350383-001-14-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.826879 | 0.017952 | -0.002769 | 0.912293 | 0.017838 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000906 |
BRD-K53414658-001-08-2 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.585406 | 0.007113 | -0.020774 | 0.791184 | 0.009944 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000906 |
BRD-K54955827-001-02-2 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.45472 | 1.570514 | 0.287437 | 0.877413 | 1.152432 | 5.318226 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000906 |
BRD-K54997624-001-06-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.711283 | 0.723771 | 0.498841 | 1 | 0.517297 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000906 |
BRD-K56981171-001-02-8 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.62598 | -0.322183 | -0.259561 | 0.822086 | 0.05442 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000906 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.